Hyperkalaemia clinical trials

Explore recruiting hyperkalaemia clinical trials.

Recruiting hyperkalaemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hyperkalaemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An open-label study to assess safety and efficacy of SZC in paediatric patients with hyperkalaemia

Germany, Romania, Spain, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

(22267) A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease and type 1 diabetes

Italy, Germany, Denmark, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children under 12 Years of Age with Hyperkalaemia (EMERALD2)

Slovakia, Greece, France, Hungary, Belgium, Finland +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Prospective, double-blind, randomized, single centre trial to evaluate the rate of RAAS inhibitor withdrawal or down-titration in non-dialysis patients with CKD stage IIIB to Vrandomized to Patiromer or placebo

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Initiation of angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF): the INITIATE-HFrEF randomized open-label trial

Portugal

Phase III and phase IV (Integrated) EU CTIS Study details

Randomized controlled trial evaluating the impact of mineralocorticoid receptor blockade by eplerenone on echocardiographic abnormalities among kidney graft recipient under calcineurin inhibitors. KT-CANOPY: Cardiac improvement by eplerenone among patients under cyclosporine or tacrolimus for kidney transplantation.

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hyperkalaemia trials by city

Hyperkalaemia in Toronto Hyperkalaemia in Vancouver Hyperkalaemia in Montreal Hyperkalaemia in Calgary Hyperkalaemia in Edmonton Hyperkalaemia in Ottawa Hyperkalaemia in Winnipeg Hyperkalaemia in Quebec City Hyperkalaemia in Hamilton Hyperkalaemia in Kitchener Hyperkalaemia in London Hyperkalaemia in Halifax Hyperkalaemia in New York Hyperkalaemia in Los Angeles Hyperkalaemia in Chicago Hyperkalaemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease